New trial tailors anal cancer treatment for people with HIV
NCT ID NCT04929028
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after standard treatment. The study will monitor side effects and cancer recurrence in 40 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II RECTAL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
George Washington University Medical Center
Washington D.C., District of Columbia, 20037, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Mount Sinai West
New York, New York, 10019, United States
-
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine, mitomycin, fluorouracil, nivolumab, intensity modulated radiation therapy
What this could lead to
If successful, this could lead to a more effective treatment plan that reduces the chance of anal cancer returning in people with HIV.
What could go wrong
This is a small, early-phase trial (40 participants) focused on safety and side effects, not yet proven to improve outcomes. Adding immunotherapy may increase side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.